All In MedTech

FDA Clearance Tracker · P160019

Elecsys HBsAg II/Elecsys HBsAg Confirmatory Test/ PreciControl HBsAg II

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 23, 2016 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P160019
Device name
Elecsys HBsAg II/Elecsys HBsAg Confirmatory Test/ PreciControl HBsAg II
Applicant location
Indianapolis, IN
Received
Jul 1, 2016
Decided
Dec 23, 2016
Decision
Approved (reclassified)
Supplements
19 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3172

Every decision under product code LOM

FDA's approval statement

As written in FDA's record.

Approval for the Elecsys Hbsag II, Elecsys HBsAg Confirmatory Test, and PreciControl HBsAg II. This device is indicated for:Elecsys HBsAg II Immunoassay for the in vitro qualitative detection of hepatitis B surface antigen (HBsAg) in human adult and pediatric (2 to 21 years of age) serum and plasma (sodium heparin, lithium heparin, K2 EDTA, sodium citrate). Assay results, in conjunction with other serological and clinical information, may be used for the laboratory diagnosis of individuals at risk for infection with HBV or with signs and symptoms of hepatitis. In addition, this assay may be used to screen for hepatitis B infection in pregnant women to identify neonates at high risk of acquiring HBV during the perinatal period.The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 601 immunoassay analyzer.Elecsys HBsAg Confirmatory TestFor Elecsys HBsAg Confirmatory Test used with Elecsys HBsAg immunoassay:Immunoassay for in vitro qualitative confirmation of the presence of hepatitis B surface antigen in human serum and plasma (sodium heparin, K3 EDTA, sodium citrate) samples repeatedly reactive when tested with the Elecsys HBsAg immunoassay. This assay is intended for use on the Elecsys and cobas e immunoassay analyzers.For Elecsys HBsAg Confirmatory Test used with Elecsys HBsAg II:Immunoassay for in vitro qualitative confirmation of the presence of hepatitis B surface antigen in human serum and plasma (sodium heparin, lithium heparin, K2 EDTA, sodium citrate) samples repeatedly reactive when tested with Elecsys HBsAg II. This assay is intended for use on the cobas e 601 immunoassay analyzer.PreciControl HBsAg IIPreciControl HBsAg II is used for quality control of the Elecsys HBsAg II immunoassay on the cobas e 601 immunoassay analyzer. The performance of PreciControl HBsAg II has not been established with any other HBsAg assay.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LOM. The earliest in FDA's data is P780016-S002, decided Mar 17, 1980.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Roche Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.